Phage therapy of pseudomonas infections
AssigneePherecydes Pharma
InventorsFlavie Pouillot, Hélène Blois
Life of this patent
Estimating the term…
Abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
Claims22
A method of treating a mammal comprising the administration to said mammal of a composition comprising at least two distinct bacteriophages having lytic activity to a Pseudomonas aeruginosa (P. aeruginosa) strain, said at least two distinct bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 13 or a sequence having at least 90%97% identity thereto.
A method of modifying the microbial flora in a mammal comprising the administration to said mammal of a composition comprising at least two distinct bacteriophages having lytic activity to a Pseudomonas aeruginosa (P. aeruginosa) strain, said at least two distinct bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 13 or a sequence having at least 97% identity thereto.
A method for preparing an antibacterial composition comprising at least two distinct bacteriophages having lytic activity to a Pseudomonas aeruginosa (P. aeruginosa) strain, said method comprising separately producing one or more of said at least two bacteriophages comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 13 or a sequence having at least 97% identity thereto and combining said one or more of said at least two bacteriophages with a suitable carrier or excipient.
A bacteriophage having lytic activity to a Pseudomonas aeruginosa (P. aeruginosa) strain and having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 13 or a sequence having at least 97% identity thereto.
Dependencies are inferred from the claim text.